{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:59:03Z","timestamp":1768478343060,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.schres.2015.07.048","type":"journal-article","created":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T21:33:08Z","timestamp":1439415188000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002\u20132012)"],"prefix":"10.1016","volume":"168","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ai","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor S.","family":"Ungvari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen F.K.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gao-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Shen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Zhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Guo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Yi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Mei","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2015.07.048_bb0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/09540261.2010.515205","article-title":"Sex differences in schizophrenia","volume":"22","author":"Abel","year":"2010","journal-title":"Int. Rev. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.07.048_bb0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2015.07.048_bb0015","series-title":"Practice guideline for the treatment of patients with schizophrenia","author":"APA","year":"1997"},{"issue":"5","key":"10.1016\/j.schres.2015.07.048_bb0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2015.07.048_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pnpbp.2011.10.008","article-title":"Insight into illness, neurocognition and quality of life in schizophrenia","volume":"36","author":"Boyer","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2015.07.048_bb0035","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"4","key":"10.1016\/j.schres.2015.07.048_bb0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","article-title":"Clinical predictors of therapeutic response to antipsychotics in schizophrenia","volume":"16","author":"Carbon","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2015.07.048_bb0045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jclp.20872","article-title":"The role of subjective illness beliefs and attitude toward recovery within the relationship of insight and depressive symptoms among people with schizophrenia spectrum disorders","volume":"68","author":"Cavelti","year":"2012","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.schres.2015.07.048_bb0050","series-title":"Guideline for the prevention and treatment of psychiatric disorders in China","author":"Chinese Medical Association","year":"2003"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1440-1819.2004.01194.x","article-title":"Antipsychotic drug prescription for schizophrenia in East Asia: Rationale for change","volume":"58","author":"Chong","year":"2004","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2015.07.048_bb0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","article-title":"Evaluation of treatment-resistant schizophrenia","volume":"23","author":"Conley","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2015.07.048_bb0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2015.07.048_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.schres.2015.07.048_bb0075","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00228-004-0835-z","article-title":"Continuing clozapine treatment despite neutropenia","volume":"60","author":"Esposito","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2015.07.048_bb0080","first-page":"CD000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","volume":"1","author":"Essali","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2015.07.048_bb0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14740338.2012.683523","article-title":"Safety and tolerability of antipsychotic polypharmacy","volume":"11","author":"Gallego","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.schres.2015.07.048_bb0095","series-title":"ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338 US Department of Health, Education, and Welfare, Washington, DC","author":"Guy","year":"1976"},{"issue":"4","key":"10.1016\/j.schres.2015.07.048_bb0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00023210-200620040-00003","article-title":"The SOHO (Schizophrenia Outpatient Health Outcome) study: Implications for the treatment of schizophrenia","volume":"20","author":"Haro","year":"2006","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.schres.2015.07.048_bb0105","first-page":"395","article-title":"Risperidone as an adjunct to clozapine therapy in chronic schizophrenics","volume":"57","author":"Henderson","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2015.07.048_bb0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.schres.2015.07.048_bb0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"issue":"7935","key":"10.1016\/j.schres.2015.07.048_bb0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Letter: Clozapine and agranulocytosis","volume":"2","author":"Idanpaan-Heikkila","year":"1975","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: A clinical review of adverse effects and management","volume":"15","author":"Iqbal","year":"2003","journal-title":"Ann. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/135581969700200105","article-title":"Development and testing of the UK SF-12 (short form health survey)","volume":"2","author":"Jenkinson","year":"1997","journal-title":"J. Health Serv. Res. Policy"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am. J. Psychiatr."},{"issue":"9","key":"10.1016\/j.schres.2015.07.048_bb0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy","volume":"8","author":"Kane","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2015.07.048_bb0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/appi.ajp.158.2.311","article-title":"Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatr."},{"issue":"4","key":"10.1016\/j.schres.2015.07.048_bb0155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1176\/appi.ajp.159.4.567","article-title":"Racial disparities in antipsychotic prescription patterns for patients with schizophrenia","volume":"159","author":"Kuno","year":"2002","journal-title":"Am. J. Psychiatr."},{"issue":"9896","key":"10.1016\/j.schres.2015.07.048_bb0160","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2015.07.048_bb0165","first-page":"507","volume":"24","author":"Liang","year":"2004"},{"key":"10.1016\/j.schres.2015.07.048_bb0170","first-page":"289","article-title":"The comparison of use of antipsychotics in first-episode patients with schizophrenia (in Chinese)","volume":"15","author":"Liu","year":"2003","journal-title":"Med. J. Chin. People Health"},{"issue":"6","key":"10.1016\/j.schres.2015.07.048_bb0175","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/00048674.2011.561482","article-title":"Clozapine prescription patterns in Australia over the last 10years","volume":"45","author":"Malalagama","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.07.048_bb0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.psychres.2014.11.016","article-title":"Quality of life in schizophrenia spectrum disorders: Associations with insight and psychopathology","volume":"225","author":"Margariti","year":"2015","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2015.07.048_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.07.001","article-title":"New therapeutic approaches for treatment-resistant schizophrenia: A look to the future","volume":"58","author":"Miyamoto","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.schres.2015.07.048_bb0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YCO.0000000000000159","article-title":"Schizophrenia: When clozapine fails","volume":"28","author":"Miyamoto","year":"2015","journal-title":"Curr. Opin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0200","first-page":"11","article-title":"\u201cSchizophrenia past clozapine\u201d: Reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing","volume":"48","author":"Mustafa","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2015.07.048_bb0205","first-page":"1069","article-title":"TESS (Treatment Emergent Symptom Scale-write-in)","volume":"21","author":"National Institute of Mental Health","year":"1985","journal-title":"Psychopharmacol. Bull."},{"issue":"8","key":"10.1016\/j.schres.2015.07.048_bb0210","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bdi.12018","article-title":"Real-world effectiveness of clozapine in patients with bipolar disorder: Results from a 2-year mirror-image study","volume":"14","author":"Nielsen","year":"2012","journal-title":"Bipolar Disord."},{"issue":"6","key":"10.1016\/j.schres.2015.07.048_bb0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1742-1241.1995.tb10004.x","article-title":"Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder","volume":"49","author":"Puri","year":"1995","journal-title":"Br. J. Clin. Pract."},{"issue":"10","key":"10.1016\/j.schres.2015.07.048_bb0220","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00023210-200519100-00004","article-title":"Augmentation strategies in clozapine-resistant schizophrenia","volume":"19","author":"Remington","year":"2005","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.schres.2015.07.048_bb0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.comppsych.2011.07.003","article-title":"Depression and quality of life in first-episode psychosis","volume":"53","author":"Renwick","year":"2012","journal-title":"Compr. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.07.048_bb0230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/oxfordjournals.schbul.a007025","article-title":"Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia","volume":"29","author":"Rothbard","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2015.07.048_bb0235","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","article-title":"What is an adequate trial with clozapine?: Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia","volume":"42","author":"Schulte","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2015.07.048_bb0240","first-page":"137","article-title":"Use of psychotropic medications in hospitalized patients with schizophrenia (in Chinese)","volume":"31","author":"Shao","year":"2011","journal-title":"China Pract. Med."},{"key":"10.1016\/j.schres.2015.07.048_bb0245","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.07.048_bb0250","first-page":"152","article-title":"Antipsychotic drug patterns of schizophrenia in China: A cross-sectional study (in Chinese)","volume":"37","author":"Si","year":"2004","journal-title":"Chin. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.07.048_bb0255","series-title":"The Maudsley prescribing guidelines","author":"Taylor","year":"2003"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0033291797005874","article-title":"Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability","volume":"28","author":"Voruganti","year":"1998","journal-title":"Psychol. Med."},{"issue":"6","key":"10.1016\/j.schres.2015.07.048_bb0265","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ajp.2009.09030358","article-title":"Risperidone maintenance treatment in schizophrenia: A randomized, controlled trial","volume":"167","author":"Wang","year":"2010","journal-title":"Am. J. Psychiatr."},{"issue":"1\u20133","key":"10.1016\/j.schres.2015.07.048_bb0270","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2010.03.005","article-title":"Correlates, change and \u2018state or trait\u2019 properties of insight in schizophrenia","volume":"122","author":"Wiffen","year":"2010","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2015.07.048_bb0275","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2015.07.048_bb0280","doi-asserted-by":"crossref","first-page":"e66154","DOI":"10.1371\/journal.pone.0066154","article-title":"Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009","volume":"8","author":"Xiang","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.schres.2015.07.048_bb0285","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3109\/00048674.2011.607426","article-title":"Clozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009","volume":"45","author":"Xiang","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0290","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1286345","article-title":"Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001\u20132009)","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.07.048_bb0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hup.821","article-title":"Clinical correlates of clozapine prescription for schizophrenia in China","volume":"22","author":"Xiang","year":"2007","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2015.07.048_bb0300","first-page":"257","article-title":"The clinical characteristics of patients with treatment-resistant schizophrenia (in Chinese)","volume":"17","author":"Yang","year":"2005","journal-title":"Med. J. Chin. People's Health"},{"issue":"3","key":"10.1016\/j.schres.2015.07.048_bb0305","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","article-title":"Management of the adverse effects of clozapine","volume":"24","author":"Young","year":"1998","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.schres.2015.07.048_bb0310","first-page":"411","article-title":"Clozapine in severe mood disorders","volume":"56","author":"Zarate","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2015.07.048_bb0315","first-page":"226","article-title":"Reliability and validity of SF-12 among floating population (in Chinese)","volume":"27","author":"Zhang","year":"2011","journal-title":"Chin. J. Public Health"},{"key":"10.1016\/j.schres.2015.07.048_bb0320","first-page":"207","article-title":"A survey of antipsychotic combination therapy and its related factors in China in 2006 (in Chinese)","volume":"45","author":"Zhang","year":"2012","journal-title":"Chin. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415004144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415004144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T03:32:37Z","timestamp":1691897557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415004144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":64,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0920996415004144"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.07.048","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002\u20132012)","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.07.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}